The IPO Buzz: Lycia Therapeutics (LYCA Proposed) Sets Terms for $250 Million IPO
Lycia Therapeutics (LYCA Proposed), a Phase 1 biotech targeting allergies and Graves’ disease, set the terms for its $250 million IPO early today – Tuesday, Oct. 20, 2026. The company is offering 14.7 million shares at a price range of $16.00 to $18.00 to raise $249.9 million, if priced at the $17.00 mid-point. This is a NASDAQ listing - set to price this week. Please see our IPO Calendar f..
Read more October 20, 2026IPO Calendar
| Company | Symbol proposed | Shares (Millions) | Est. $ Volume | Expected to Trade | SCOOP Rating | Rating Change |
|---|---|---|---|---|---|---|
| Bitari | BIAI | 4.3 | $ 30.0 mil | 10/19/2026 Week of | S/O | S/O |
| Lycia Therapeutics | LYCA | 14.7 | $ 249.9 mil | 10/23/2026 Friday | S/O | S/O |
| Primagrove | YNTE | 6.3 | $ 30.5 mil | 11/9/2026 Week of | S/O | S/O |
Last 100 IPOs - October 20, 2026
| Number of IPOs priced : | 100 |
| Number Up: | 41 |
| Number Down: | 57 |
| Number Unchanged: | 2 |
| Percentage Change From Issue Price: | -0.94% |
| Percentage Change for The Nasdaq Composite | 35.22% |
2026 IPO Scorecard - October 20, 2026
| Number of IPOs priced (Excluding 152 units) : | 132 |
| Number Up: | 50 |
| Number Down: | 80 |
| Number Unchanged: | 2 |
| Total Return From Issue Price: | -1.88% |
| The Nasdaq Composite Index YTD % Change | 35.22% |